Skip to content
FDAMedical devices

Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses in the U.S.

FDA recall n-bausch-lomb-announces-voluntary-recall-envista-aspiretm-envista-envytm-and-certa ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

Check my lot or code

Is yours in this recall?

Type the lot, batch, date code, model number or UPC printed on the product. It is compared here, in your browser, with the codes this notice lists. It stays in this page: it is not added to the address.

General information on recalls from the agency: U.S. Food and Drug Administration (opens in a new tab).

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

Increased frequency of reports of toxic anterior segment syndrome
Text from FDA, unedited.

The recalled product

Codes in the record. Click one to copy it.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) on its enVista platform.
Text from FDA, unedited.

Company announcement, as FDA publishes it

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) on its enVista platform. This action was taken after the company received reports of complications, the cause of which could not immediately be explained.

“As much as we believe in the enVista platform, patient safety will always be our number one priority,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Surgeons and patients trust Bausch + Lomb, and I believe that this voluntary recall is the best thing we can do to honor that trust.”

The recall is in response to an increased number of reports of toxic anterior segment syndrome (TASS), and includes all lots of the following enVista Aspire, enVista Aspire Toric, enVista Envy and enVista Envy Toric, as well as enVista monofocal and enVista monofocal Toric IOL models in the U.S.

TASS, a potential complication in any cataract surgery, is an inflammatory reaction inside the eye that can have a variety of causes. When it occurs, this complication typically appears 12 – 48 hours after eye surgery. All enVista TASS cases reported to Bausch + Lomb to date responded quickly to treatment, and none have required removal of the lens.

“These reports represent only 1-2% of implanted lenses, with a positive prognosis for everyone involved,” Saunders continued. “We look forward to identifying a root cause and bringing the enVista platform back to market.”

Communications to eye care professionals are underway, with instructions for product return. Click here for a message from Saunders to customers, here for a copy of the U.S. version of the recall notice and here for a TASS fact sheet.

For Patients : Cataract surgery patients experiencing eye discomfort should contact their eyecare professional immediately.

For Eyecare Professionals : Please continue to closely monitor cataract surgery patients for at least 48 hours after surgery. Please instruct patients with new or worsening symptoms to contact your office immediately.

To report an adverse event, please contact Bausch + Lomb Customer Service at 1-800-338-2020, option 1, or submit a report to U.S. FDA’s MedWatch program (call 1-800-332-1088 to request a form). For more information about this recall, please contact Bausch + Lomb Customer Service at 1-800-338-2020, option 9, 8:00 am to 4:30 pm Eastern, Monday through Friday.

Text from FDA (the company’s words), unedited.
  • enVista Monofocal IOL; All models starting with EE

    Lot or code
    Model Description: enVista Monofocal IOL; Model Identifier:: All models starting with EE; Lots: ALL; UDI-DI: Click here for UDI list
  • enVista Aspire IOL; All models starting with EA

    Lot or code
    Model Description: enVista Aspire IOL; Model Identifier:: All models starting with EA
  • enVista Envy IOL; All models starting with EN

    Lot or code
    Model Description: enVista Envy IOL; Model Identifier:: All models starting with EN
  • enVista Monofocal Toric IOL; All models starting with ETE

    Lot or code
    Model Description: enVista Monofocal Toric IOL; Model Identifier:: All models starting with ETE
  • enVista Aspire Toric IOL; All models starting with ETA

    Lot or code
    Model Description: enVista Aspire Toric IOL; Model Identifier:: All models starting with ETA
  • enVista Envy Toric IOL; All models starting with ETN

    Lot or code
    Model Description: enVista Envy Toric IOL; Model Identifier:: All models starting with ETN

Source

Issued by
U.S. Food and Drug Administration
Firm
Bausch + Lomb Corporation

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Month: April 2025, Week 2025-W14. Browse more medical devices recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Increased frequency of reports of toxic anterior segment syndrome”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

How do I know if my product is included?

Compare the lot or code printed on your product with the codes FDA lists on this notice, product by product.

How does the code check on this page work?

You type the lot, batch, date code, model number or UPC from your package and the page compares it, in your browser, with the codes FDA lists on this notice. It reports a match, a possible match (your code is part of a longer listed code) or no match. It only compares text: a notice that describes products by dates, sizes or “all lots” cannot be compared, so “no match” does not clear a product. The comparison runs in your browser and the page does not send the code anywhere, and the code stays out of the page address. Only if you press “Copy link to this result” is a link made that carries it, and whoever opens that link requests that address from this site.

When was this recall published?

FDA published this company announcement on April 3, 2025.